118 results
424B4
SNGX
Soligenix Inc
19 Apr 24
Prospectus supplement with pricing info
4:05pm
of the health care community, including physicians, about the safety and effectiveness of our drug product; cost-effectiveness of our product relative … and the medical community may not accept and utilize any of our product candidates. If our products do not achieve market acceptance, we will not be able
8-K
EX-99.1
SNGX
Soligenix Inc
3 Apr 24
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study
4:05pm
this second study will both substantiate and improve upon these results. Given our extensive engagement with the CTCL community, our esteemed Medical
424B4
dxpul
5 May 23
Prospectus supplement with pricing info
6:43pm
8-K
EX-99.1
84jhnsx42 dia
15 Dec 22
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
8:14am
424B5
ysg8jh zy
13 Aug 21
Prospectus supplement for primary offering
4:11pm